Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.

University of Toronto, Toronto, Ontario, M5S 1A8, Canada.
Pharmacogenomics (Impact Factor: 3.43). 11/2007; 8(10):1385-402. DOI: 10.2217/14622416.8.10.1385
Source: PubMed

ABSTRACT Nicotine is the psychoactive substance responsible for tobacco dependence. It is also a therapeutic used to aid smoking cessation. Cytochrome P450 (CYP)2A6 is the human hepatic enzyme that mediates most of nicotine's metabolic inactivation to cotinine. Genetic variation in the CYP2A6 gene can increase or decrease enzyme activity through altering the protein's expression level or its structure and function. This article reviews CYP2A6 genetic variation and its impact on in vivo nicotine kinetics, including a description of the individual variants, different phenotyping approaches for assessing in vivo CYP2A6 activity and other sources of variation in nicotine metabolism such as gender. In addition, the effect of CYP2A6 polymorphisms on smoking behavior and tobacco-related lung cancer risk are briefly described. Furthering knowledge in this area will improve interpretation of studies examining smoking behavior, as well as those using nicotine as a therapeutic agent.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND Epigenetic events play a major role in the carcinogenesis of tobacco-related cancers. The authors conducted a retrospective cohort study to evaluate the effects of exposure to the anticonvulsant agent valproic acid (VPA), a histone deacetylase inhibitor, on the risk of developing cancers of the lung, head and neck, prostate, bladder, and colon.METHODS The study was based on the 2002 through 2008 National Veterans Affairs (VA) medical SAS data set linked to the VA Central Cancer Registry. The cohort was defined as subjects aged > 40 years who were followed in the VA system for at least 1 year for 1 of 4 diagnoses for which a VPA indication exists (bipolar disorder, posttraumatic stress disorder, migraines, and seizures). Multivariable Cox proportional hazards models were used to estimate hazards ratios (HR) and 95% confidence intervals (95% CI) reflecting the association between use of VPA and cancer incidence.RESULTSVPA use was associated with a significant reduction in the risk of cancers of the head and neck (HR, 0.66; 95% CI, 0.48-0.92). Additional associations were noted with the duration of treatment and median VPA drug levels. No significant differences in cancer incidence were observed for cancers of the lung (HR, 1.00; 95% CI, 0.84-1.19), bladder (HR, 0.86; 95% CI, 0.64-1.15), colon (HR, 0.95; 95% CI, 0.74-1.22), and prostate (HR, 0.96; 95% CI, 0.88-1.12).CONCLUSIONS Use of VPA is associated with a lower risk of developing head and neck cancers. Cancer 2013. © 2013 American Cancer Society.
    Cancer 03/2014; 120(9). · 5.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Context: Nicotine metabolite ratio (NMR) is linked with smoking behaviour and quitting, but little is known about the importance of UDP-glucuronosyltransferase metabolism phenotype on NMR. Objective: To investigate the relationship between NMR and UDP-glucuronosyltransferase phenotype in a Caucasian population. Methods: Urine samples from 260 smokers were measured by UPLC-MS/MS for cotinine (COT), 3'-hydroxycotinine, COT-glucuronide and 3'-hydroxycotinine-glucuronide. UDP-glucuronosyltransferase phenotype was assessed using the proportion of metabolites present as the glucuronide. Results: A correlation was found between NMR and UDP-glucuronosyltransferase phenotype for COT (males and females) and 3'-HC in females (p < 0.0001). Conclusion: NMR is clearly influenced by UDP-glucuronosyltransferase phenotype for COT in Caucasians.
    Biomarkers 11/2014; · 2.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Growing evidence suggests that there are subpopulations of daily smokers ranging from light infrequent users to heavy daily users. In the present review we will investigate whether these differences can be explained by factors such as social context, responsiveness to environmental cues, personality traits, neurochemical and pharmacogenetic differences. We will also assess how controlled abstinence and free choice smoking paradigms in a human laboratory setting may help identify and characterize these differences and what can be learned from these models to accurately predict clinical efficacy in the later phase testing of new chemical entities for the treatment of smoking dependence.
    Current Opinion in Pharmacology 02/2014; 14:42–49. · 4.23 Impact Factor